{"id":"amperozide","rwe":[],"tags":[{"label":"amperozide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Fatty-acid amide hydrolase 1","category":"target"},{"label":"FAAH","category":"gene"},{"label":"HTR6","category":"gene"},{"label":"Active","category":"status"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["amperozide"],"offLabel":[],"synonyms":["amperozide"],"timeline":[],"ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 6, Fatty-acid amide hydrolase 1","targets":[{"gene":"FAAH","source":"DrugCentral","target":"Fatty-acid amide hydrolase 1","protein":"Fatty-acid amide hydrolase 1"},{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"}],"modality":"Small Molecule","drugClass":"amperozide","explanation":"Think of fatty acid amides as a type of chemical messenger in the brain. By blocking the enzyme that breaks them down, amperozide allows these messengers to build up and have a greater effect on the brain. This can potentially lead to changes in mood, pain perception, and other brain functions.","oneSentence":"Amperozide works by blocking an enzyme called fatty-acid amide hydrolase 1, which breaks down fatty acid amides in the brain.","technicalDetail":"Amperozide acts as a selective inhibitor of fatty-acid amide hydrolase 1 (FAAH1), a key enzyme involved in the hydrolysis of fatty acid amides, including anandamide and oleoylethanolamide. By inhibiting FAAH1, amperozide increases the levels of these endogenous lipids, which can modulate various physiological processes, including pain perception, mood regulation, and inflammation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/193","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMPEROZIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:43:09.495510","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:52:05.706274+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"dronabinol","drugSlug":"dronabinol","fdaApproval":"1985-05-31","patentExpiry":"Aug 6, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"oleic acid","drugSlug":"oleic-acid","fdaApproval":"","relationship":"same-target"},{"drugName":"propofol","drugSlug":"propofol","fdaApproval":"1989-10-02","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"amperozide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dronabinol","brandName":"dronabinol","genericName":"dronabinol","approvalYear":"1985","relationship":"same-target"},{"drugId":"oleic-acid","brandName":"oleic acid","genericName":"oleic acid","approvalYear":"","relationship":"same-target"},{"drugId":"propofol","brandName":"propofol","genericName":"propofol","approvalYear":"1989","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"0M2W3TAG39","CHEBI":"CHEBI:180480","INN_ID":"5033","UMLSCUI":"C0051747","ChEMBL_ID":"CHEMBL1079935","DRUGBANK_ID":"DB08927","PUBCHEM_CID":"73333","MESH_SUPPLEMENTAL_RECORD_UI":"C049058"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":118,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"AMPEROZIDE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amperozide is a small molecule drug that targets fatty-acid amide hydrolase 1 (FAAH1), a key enzyme involved in the breakdown of fatty acid amides. It is classified as an amperozide, but its exact commercial status and approved indications are unknown. The mechanism of action of amperozide is not well-documented, but it is believed to work by inhibiting the activity of FAAH1, leading to increased levels of certain fatty acid amides in the brain. As a result, amperozide may have therapeutic effects on various conditions, although its specific uses and efficacy are not well-established. Further research is needed to fully understand the properties and potential applications of amperozide.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:52:05.706274+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}